Efficacy of regorafenib combined with PD-1 inhibitors in elderly patients with advanced metastatic colorectal cancer

BMC Geriatrics

Research

Jinxi Huang¹  Xiaobing Chen²  Caiyun Nie²  Jing Zhao²  Huifang Lv²  Beibei Chen²  Saiqi Wang²  Yunduan He²  Weifeng Xu²  Huichen Zhao²  Jianzheng Wang² 

[1] Department of Gastrointestinal Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, 450008, Zhengzhou, Henan Province, China;Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, 450008, Zhengzhou, Henan Province, China;Zhengzhou Key Laboratory for Precision Therapy of Gastrointestinal Cancer, 450008, Zhengzhou, Henan Province, China;

关键词: Colorectal cancer;    Elderly patients;    Immunotherapy;    Programmed cell death protein 1;    Regorafenib;   

DOI  :  10.1186/s12877-022-03637-9

 received in 2022-01-18, accepted in 2022-11-18,  发布年份 2022

来源: Springer

【 摘 要 】

ObjectiveThis is the first clinical study that wants to investigate the treatment patterns, clinical outcomes, and prognostic factors of regorafenib plus PD-1 inhibitors therapy in Chinese elderly patients with advanced colorectal cancer.MethodsA cohort of metastatic colorectal cancer patients 60 years or older who received treatment with regorafenib combined with PD-1 inhibitors was included in our analysis. The endpoints included overall survival (OS), progression-free survival (PFS), and prognostic factors.ResultsIn total, 24 patients were enrolled with the median age of 68 years, and 62.5% were female. The median OS and PFS were 15.03 months (95% CI 7.0–23.0) and 4.0 months (95% CI 1.8–6.2), respectively. The objective response rate was 8.3%, and the disease control rate was 70.8%. Patients previously treated with regorafenib had a longer median PFS than those without (6.3 versus 2.8 months). In terms of final daily doses, it showed a trend toward better PFS (median PFS was 10.0 months) in high-dose group (daily dose above 80 mg of regorafenib) compared to low-dose group (daily dose no more than 80 mg of regorafenib) (median PFS was 3.5 months).ConclusionsThis real-world evidence confirms that Chinese elderly patients with advanced colorectal cancer may benefit from the treatment of regorafenib combined with PD-1 inhibitors, similarly with this combination therapy strategies in all age patients.

【 授权许可】

CC BY   
© The Author(s) 2022